A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice

Abstract The spread of SARS-CoV-2 has caused a global pandemic that has affected almost every aspect of human life. The development of an effective COVID-19 vaccine could limit the morbidity and mortality caused by infection, and may enable the relaxation of social distancing measures. Age is one of...

Full description

Saved in:
Bibliographic Details
Published in:bioRxiv 2020-10
Main Authors: Silva-Cayetano, Alyssa, Foster, William S, Innocentin, Silvia, Belij-Rammerstorfer, Sandra, Spencer, Alexandra J, Burton, Oliver T, Fra-Bidó, Sigrid, Jia Le Lee, Thakur, Nazia, Conceicao, Carina, Wright, Daniel, Jordan Barett, Evans-Bailey, Nicola, Noble, Carly, Bailey, Dalan, Liston, Adrian, Gilbert, Sarah C, Lambe, Teresa, Linterman, Michelle A
Format: Article
Language:English
Subjects:
Coronaviruses
COVID-19
COVID-19 vaccines
Humoral immunity
Immune response
Immunogenicity
Morbidity
Older people
Pandemics
Patent applications
Risk factors
Severe acute respiratory syndrome coronavirus 2
Vaccines
Citations: Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The spread of SARS-CoV-2 has caused a global pandemic that has affected almost every aspect of human life. The development of an effective COVID-19 vaccine could limit the morbidity and mortality caused by infection, and may enable the relaxation of social distancing measures. Age is one of the most significant risk factors for poor health outcomes after SARS-CoV-2 infection, therefore it is desirable that any new vaccine candidates should elicit a robust immune response in older adults. Here, we test the immunogenicity of the adenoviral vectored vaccine ChAdOx1 nCoV-19 (AZD-1222) in aged mice. We find that a single dose of this vaccine induces cellular and humoral immunity in aged mice, but at a reduced magnitude than in younger adult mice. Furthermore, we report that a second dose enhances the immune response to this vaccine in aged mice, indicating that a primeboost strategy may be a rational approach to enhance immunogenicity in older persons. Competing Interest Statement Sarah Gilbert and Teresa Lambe are named on a patent application covering ChAdOx1 nCoV-19. The remaining authors declare no competing interests. The funders played no role in the conceptualisation, design, data collection, analysis, decision to publish, or preparation of the manuscript. Footnotes * ↵* Joint first authors * ↵^ Joint authors * ↵§ Joint senior authors
DOI:10.1101/2020.10.27.357426